Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV

References

• Hesketh PJ, Bohlke K, Lyman GH. Antiementics: Americian Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2016;34:381–386. doi:10.1200/JCO.2015.64.3635
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer. 2006;14(4):354–360. doi:10.1007/s00520-005-0914-4
   Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed October 12, 2020.
   Google Scholar
• Babaoglu MO, Bayar B, Aynacioglu AS, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5‐hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther. 2005;78(6):619–626. doi:10.1016/j.clpt.2005.08.015
   Web of Science ®Google Scholar
• Zoto T, Kilickap S, Yasar U, et al. Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter. Basic Clin Pharmacol Toxicol. 2015;116(4):354–360. doi:10.1111/bcpt.12334
   PubMed Web of Science ®Google Scholar
• He H, Yin J, Xu Y, et al. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting. Clin Ther. 2014;36(8):1242–1252. doi:10.1016/j.clinthera.2014.06.016
   PubMed Web of Science ®Google Scholar
• Tsuji D, Kim Y, Nakamichi H, et al. Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients. Drug Metab Pharmacokinet. 2013;28(4):299–304. doi:10.2133/dmpk.DMPK-12-RG-084
   PubMed Web of Science ®Google Scholar
• Tsuji D, Yokoi M, Suzuki K, et al. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. Pharmacogenomics J. 2017;17(5):435–440. doi:10.1038/tpj.2016.38
   PubMed Web of Science ®Google Scholar
• Tsuji D, Matsumoto M, Kawasaki Y, et al. Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy. Cancer Chemother Pharmacol. 2021;87(1):73–83. doi:10.1007/s00280-020-04177-y
   PubMed Web of Science ®Google Scholar
• Mukoyama N, Yoshimi A, Goto A, et al. An analysis of behavioral and genetic risk factors for chemotherapy-induced nausea and vomiting in Japanese subjects. Biol Pharm Bull. 2016;39(11):1852–1858. doi:10.1248/bpb.b16-00440
   PubMed Web of Science ®Google Scholar
• Lamba JK, Fridley BL, Ghosh TM, et al. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics. 2014;15(12):1565–1574. doi:10.2217/pgs.14.107
   PubMed Web of Science ®Google Scholar
• Mccrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74(1):17–24. doi:10.1016/S0009-9236(03)00066-3
   PubMed Web of Science ®Google Scholar
• Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188–195. doi:10.1016/j.suponc.2011.05.002
   PubMedGoogle Scholar
• Ithimakin S, Theeratrakul P, Laocharoenkiat A, et al. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer. 2020;28(11):5335–5342. doi:10.1007/s00520-020-05380-6
   PubMed Web of Science ®Google Scholar
• Rumyantsev A, Glazkova E, Nasyrova R, et al. Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: final results of randomized Phase II trial. J Clin Oncol. 2019;37(15_suppl):11504. doi:10.1200/JCO.2019.37.15_suppl.11504
   Web of Science ®Google Scholar
• Li Q, Wang W, Chen G, et al. Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting. Open Med (Wars). 2018;13:29–34. doi:10.1515/med-2018-0005
   Google Scholar
• Mosa ASM, Hossain AM, Lavoie BJ, et al. Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol. 2020;11:329. doi:10.3389/fphar.2020.00329
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 2020;21(2):242–249. doi:10.1016/S1470-2045(19)30678-3
   PubMed Web of Science ®Google Scholar
• Liu L, Ding C, Wang J, et al. Low dose olanzapine can improve delayed nausea and vomiting induced by high emetogenic chemotherapy in female patients with lung cancer. J Oncol. 2017;23(03):251–253.
   Google Scholar
• Abe M, Hirashima Y, Kasamatsu Y, et al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer. 2016;24(2):675–682. doi:10.1007/s00520-015-2829-z
   Web of Science ®Google Scholar
• Saiz-Rodríguez M, Belmonte C, Román M, et al. Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol. 2018;123(4):474–485. doi:10.1111/bcpt.13031
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sakaeda T, Horinouchi M, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002;71(4):297–303. doi:10.1067/mcp.2002.122055
   PubMed Web of Science ®Google Scholar
• Perwitasari DA, Gelderblom H, Atthobari J, et al. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm. 2011;33(1):33–43. doi:10.1007/s11096-010-9454-1
   PubMed Web of Science ®Google Scholar
• Chowbay B, Li H, David M, et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol. 2005;60(2):159–171. doi:10.1111/j.1365-2125.2005.02392.x
   PubMed Web of Science ®Google Scholar
• Janicki PK, Sugino S. Genetic factors associated with pharmacotherapy and background sensitivity to postoperative and chemotherapy-induced nausea and vomiting. Exp Brain Res. 2014;232(8):2613–2625. doi:10.1007/s00221-014-3968-z
   Web of Science ®Google Scholar
• Fernandez-Rozadilla C, Cazier JB, Moreno V, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 2013;13(3):209–217. doi:10.1038/tpj.2012.2
   PubMed Web of Science ®Google Scholar
• Hosák L. Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry. 2007;22(5):276–281. doi:10.1016/j.eurpsy.2007.02.002
   PubMed Web of Science ®Google Scholar
• Laugsand EA, Fladvad T, Skorpen F, et al. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur J Cancer. 2011;47(11):1682–1691. doi:10.1016/j.ejca.2011.04.014
   PubMed Web of Science ®Google Scholar